Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sopharma AD-SofiaFRA:3JR 69 Earnings per Share (Diluted) is €0.15 as of Jun. 2026. GuruFocus rates FRA:3JR with a GF Score™ of 69/100 and a GF Value™ of €1.91 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 101 Medical Distribution companies, Sopharma AD-Sofia ranks worse than 990098.02% on this metric.
Sopharma AD-Sofia's EPS (Basic) for the
three
months ended in Jun. 2026 was €0.03.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.15.
During the past 13 years, Sopharma AD-Sofia's highest 3-Year average EPS without NRI Growth Rate was 41.10% per year. The lowest was -19.30% per year. And the median was -3.00% per year.
Sopharma AD-Sofia (FRA:3JR) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Sopharma AD-Sofia Earnings per Share (Diluted) Related Terms
Sopharma AD-Sofia Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia Earnings per Share (Diluted) Chart
FRA:3JR vs MCK, COR, CAH: Earnings per Share (Diluted) Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia PE Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's PE Ratio distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's PE Ratio falls into.
Sopharma AD-Sofia Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Sopharma AD-Sofia's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.15
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of €0.15 mean?
Sopharma AD-Sofia (FRA:3JR) has a Earnings per Share (Diluted) of €0.15 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Sopharma AD-Sofia and its competitors. According to the industry distribution chart, Sopharma AD-Sofia ranks #999999 out of 101 companies in the Medical Distribution industry.
Is Sopharma AD-Sofia's Earnings per Share (Diluted) too high?
Sopharma AD-Sofia's current Earnings per Share (Diluted) is €0.15. Based on the distribution chart, Sopharma AD-Sofia ranks #999999 out of 101 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Sopharma AD-Sofia has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Earnings per Share (Diluted) compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #999999 out of 101 companies for Earnings per Share (Diluted). This places Sopharma AD-Sofia in the lower half of its industry. The industry median Earnings per Share (Diluted) is 3.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Distribution company?
The median Earnings per Share (Diluted) among Medical Distribution companies is 3.60, based on 101 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median Earnings per Share (Diluted) is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current Earnings per Share (Diluted) is €0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (FRA:3JR) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.91, compared to a current price of €2.32 — trading 21.5% above its estimated fair value. The current Earnings per Share (Diluted) is €0.15. Sopharma AD-Sofia's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Sopharma AD-Sofia (FRA:3JR), the current Earnings per Share (Diluted) is €0.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (FRA:3JR) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be overvalued.
The current stock price of €2.32 is trading 21.5% above its estimated GF Value™ of €1.91.
GuruFocus considers Sopharma AD-Sofia to be Modestly Overvalued.
Key valuation signals for FRA:3JR:
Earnings per Share (Diluted): €0.15
GF Value™: €1.91 vs. price of €2.32 (21.5% above fair value)
No single metric tells the full story. See the FRA:3JR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
69GF Score
Get the complete analysis for FRA:3JR
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3JR has been successfully added to your 
